Date published: 2025-10-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

BML-210 (CAS 537034-17-6)

0.0(0)
Write a reviewAsk a question

Alternate Names:
N1-(2-aminophenyl)-N8-phenyl-octanediamide
Application:
BML-210 is an inhibitor of HDAC activity and gene expression modulator
CAS Number:
537034-17-6
Purity:
≥98%
Molecular Weight:
339.43
Molecular Formula:
C20H25N3O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Rtn-3 Inhibitors are a class of chemical compounds specifically designed to inhibit the function of Reticulon-3 (Rtn-3), a member of the reticulon family of proteins that are primarily associated with the endoplasmic reticulum (ER). Rtn-3, like other reticulons, is involved in shaping the tubular structure of the ER and is implicated in various cellular processes, including membrane trafficking, ER stress response, and the regulation of lipid metabolism. Rtn-3 is particularly notable for its role in maintaining ER morphology and dynamics, which are critical for proper cellular function. By modulating the curvature of the ER membrane, Rtn-3 helps to regulate the ER′s interaction with other organelles and plays a role in the processing and transport of proteins and lipids within the cell. Inhibitors of Rtn-3 are valuable tools for researchers studying the intricate functions of the ER and its associated proteins. By selectively blocking Rtn-3 activity, these inhibitors allow scientists to observe the downstream effects on ER structure and function, shedding light on the protein′s role in maintaining cellular homeostasis. The use of Rtn-3 inhibitors can also reveal insights into how disruptions in ER morphology might contribute to broader cellular dysfunction. Additionally, these inhibitors help in mapping out the complex network of interactions between Rtn-3 and other proteins involved in ER processes. Through the study of Rtn-3 inhibitors, researchers can better understand the fundamental mechanisms governing ER structure, the protein′s involvement in intracellular transport, and its potential links to various cellular pathways. These inhibitors are thus critical tools in advancing our understanding of cellular biology, particularly in the context of the ER′s vital role in maintaining cell integrity and function.


BML-210 (CAS 537034-17-6) References

  1. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.  |  Herman, D., et al. 2006. Nat Chem Biol. 2: 551-8. PMID: 16921367
  2. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.  |  Savickiene, J., et al. 2006. Eur J Pharmacol. 549: 9-18. PMID: 16978604
  3. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells.  |  Borutinskaite, VV., et al. 2006. Ann N Y Acad Sci. 1091: 346-55. PMID: 17341627
  4. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model.  |  Rai, M., et al. 2008. PLoS One. 3: e1958. PMID: 18463734
  5. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.  |  Savickiene, J., et al. 2009. Ann N Y Acad Sci. 1171: 321-33. PMID: 19723072
  6. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells.  |  Savickiene, J., et al. 2012. Mol Cell Biochem. 359: 245-61. PMID: 21842375
  7. Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC cell line.  |  Xiong, P., et al. 2011. Protein J. 30: 499-508. PMID: 21947960
  8. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.  |  Borutinskaite, VV., et al. 2012. Mol Biol Rep. 39: 10179-86. PMID: 23007576
  9. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming.  |  Borutinskaitė, V. and Navakauskienė, R. 2015. Int J Mol Sci. 16: 18252-69. PMID: 26287160
  10. HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases.  |  Hull, EE., et al. 2016. Biomed Res Int. 2016: 8797206. PMID: 27556043
  11. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.  |  Goto, K., et al. 2016. Sci Rep. 6: 38407. PMID: 27910927
  12. Decreased Myocyte Enhancer Factor 2 Levels in the Hippocampus of Huntington's Disease Mice Are Related to Cognitive Dysfunction.  |  Vidal-Sancho, L., et al. 2020. Mol Neurobiol. 57: 4549-4562. PMID: 32757160
  13. A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1- pre-B-ALL.  |  Wang, Z., et al. 2020. Cell Death Dis. 11: 738. PMID: 32913188
  14. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.  |  Zhou, Z., et al. 2021. Nat Biomed Eng. 5: 1320-1335. PMID: 34725507

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

BML-210, 1 mg

sc-221369
1 mg
$90.00

BML-210, 5 mg

sc-221369A
5 mg
$272.00